In colorectal cancer, MARCHF inhibits the activation of the IL-6 signaling pathway by ubiquitinating and degrading the IL-6 receptor, thereby attenuating the development of colitis and inflammation-associated tumor progression 29. This evidence concerns the gene IL6 and colitis.